Diabetes drug shows promise for psoriatic arthritis heart risk
NCT ID NCT05988684
First seen Dec 24, 2025 · Last updated May 09, 2026 · Updated 15 times
Summary
This study tested whether adding metformin (a diabetes medicine) to standard care could slow the buildup of fatty plaques in the neck arteries of 24 people with psoriatic arthritis who do not have diabetes. Participants took metformin or standard care alone for one year. The goal was to see if metformin could reduce the risk of heart disease, a common complication of psoriatic arthritis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.